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Introduction 
This document represents an update of the last version of the Swiss Association for the Study of 
the Liver (SASL) and Swiss Society for Infectious Diseases (SSI) Expert Opinion Statement 
(EOS) on the Treatment of Chronic Hepatitis C virus (HCV) infection published online in 
June 2017 (www.sasl.ch; www.sggssg.ch, www.sginf.ch). It has been elaborated jointly by 
SASL and SSI. Recommendations are based on the results of phase 3 or selected phase 2 
clinical studies 1-30 and the European Association for the Study of the Liver (EASL) 
Recommendations on Treatment of Hepatitis C (www.easl.eu)31 as well as the 
Recommendations by the American Association for the Study of Liver Diseases (AASLD) and the 
Infectious Diseases Society of America (IDSA) (http://hcvguidelines.org)32. The reader is 
referred to these documents as well as the 'Fachinformation' approved by Swissmedic 
(www.compendium.ch or www.swissmedicinfo.ch) and the "Spezialitätenliste" of the Swiss 
Federal Office of Public Health (FOPH) (www.spezialitaetenliste.ch) for further information, 
including key references and sustained virological response (SVR) rates that can be expected 
with the different treatment regimens as well as current reimbursement. The Swiss HCV 
Advisor App (www.hcvadvisor.com) is based on this EOS and has been endorsed by SASL 
and SSI. It provides rapid information on recommended treatment regimens, costs and 
reimbursement. 
Treatment of chronic hepatitis C is a fast evolving field with rapidly changing 
recommendations. An exhaustive discussion in all aspects of HCV treatment is beyond the 
scope of this EOS. The aim of this EOS is rather to provide a practical and concise guidance 
for treating physicians with regular updates upon approval of new compounds. Expert advice 
should be sought for patients with direct acting antiviral (DAA) failure, decompensated 
cirrhosis, renal insufficiency, pre- or post-liver transplantation, other organ transplants (e.g. bone 
marrow, lung, heart, kidney) and acute hepatitis C which will not be covered. Treatment 
indications and priorities are not discussed in detail in this EOS. 
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The current update takes into account the expanded reimbursement limitations determined by the 
FOPH on July 1 and August 1, 2017. 
 
 
Reimbursement in Switzerland of the new DAAs is currently limited to: 
1. prescription by gastroenterologists, infectious diseases specialists, and selected, named 
other specialists (www.bag.admin.ch/ls-ref), if patients are treated with:  
• grazoprevir/elbasvir fixed-dose combination ± RBV (genotype 1 or 4)	  
• ritonavir-boosted paritaprevir, ombitasvir and dasabuvir ± RBV (genotype 1)	  
• ritonavir-boosted paritaprevir, ombitasvir and RBV (genotype 4)	  
2. prescription by gastroenterologists, infectious diseases specialists, and selected, named 
other specialists (www.bag.admin.ch/ls-ref) and one of the following, if patients are treated 
with a sofosbuvir containing regimen ± RBV 
a. Metavir stage ≥ 2 as determined by liver biopsy or FibroScan® on two occasions ≥ 3 
months apart (Table 2) or 
b. patients with clinically significant extrahepatic manifestations of HCV infection33 or 
c. patients with HIV and/or HBV coinfection irrespective of liver fibrosis stage or 
d. patients with intravenous drug consumption irrespective of fibrosis stage, if: 
i. they receive an opioid substitution or if they would qualify for such a substitution and 
drug intake is supervised by a physician or by a pharmacist at least during 5 
days/week or 
ii. they consume substances other than opioids while in addiction medicine care and 
directly observed DAA disposal is ensured by a physician or by a pharmacist at 
least during 5 days/week or 
e. patients with Metavir stage ≥ 2 with previous HCV treatment failure or 
f. patients before or after liver transplantation (LT) (SOF + RBV for genotypes 1-6 or 
LDV/SOF for genotype 1) or 
g. patients with recurrent hepatitis C post-LT (LDV/SOF for genotype 1). 
For all other indications reimbursement has to be negotiated with health insurances on an 
individual basis. There is growing evidence that extrahepatic manifestations of HCV infection 
(reviewed in 34, 35) contribute considerably to morbidity and mortality and, therefore, justify to 
treat chronic hepatitis C regardless of fibrosis stage. 
In recent years, many patients chose to buy DAAs using internet resources due to high costs 
and reimbursement restrictions. It is important that these patients contact a specialized 
physician for guidance on diagnosis and treatment of HCV infection. If patients chose to buy 
DAAs abroad, it is crucial that treatment monitoring is performed according to national and 
international recommendations. A guidance for the use of DAAs purchased abroad is 
provided at www.hepatitis-schweiz.ch/de/medikamente-online-kaufen. 
Universal treatment irrespective of fibrosis stage is recommended by the current AASLD-IDSA 
guidance (http://hcvguidelines.org). Hence, we urge all parties involved to pursue a constructive 
dialogue to enable universal access to treatment for all patients. 
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Background 
HCV chronically infects 60-80 million individuals worldwide36. Detailed information on HCV 
prevalence and on diagnosis rates are not yet available in Switzerland. However, a report 
commissioned by the FOPH, summarizing the current literature regarding HCV prevalence in 
Switzerland, has been published37. According to this report, it is estimated that 36,000-43,000 
persons are chronically infected with HCV in Switzerland. 
Recommendations for healthcare provider-initiated testing for HCV infection have been issued by 
the Swiss Experts in Viral Hepatitis (SEVHep) and the FOPH38 and complementary birth 
cohort-based screening is being discussed39. A national hepatitis C strategy has been 
conceived (www.hepatitis-schweiz.ch). 
The clinical course of chronic hepatitis C depends on a number of modifiable (alcohol, 
coinfections with hepatitis B virus or HIV, non-alcoholic fatty liver disease) and unmodifiable 
factors (age at the time of infection, sex, genotype 3, host genetics); 2-20% may develop 
cirrhosis over the first 20 years of infection, and disease progression may be accelerated in a 
non-linear fashion thereafter, with an estimated 15-30% developing cirrhosis after 30 years. It 
is expected that the peak of the disease burden (decompensated liver cirrhosis hepatocellular 
carcinoma [HCC], LT and mortality) will be reached in Switzerland only around 2030, unless 
more efficient means of screening and treatment for those in need of therapy are 
implemented 40, 41. 
 
 
Pre-treatment assessment 
Before starting antiviral treatment, other causes that contribute to the progression of liver disease 
should be carefully evaluated. All patients should be tested for hepatitis B virus (HBV) (HBsAg, 
anti-HBc, anti-HBs), as well as human immunodeficiency virus (HIV) infection. In patients 
who are HBsAg positive as well as in HBsAg-negative, anti-HBc-positive patients, a HBV DNA 
test should be obtained, whereas all patients without previous HBV exposure should be 
vaccinated. 
Hepatitis B reactivation has been rarely observed in HBsAg-and/or anti-HBc-positive patients 
during antiviral treatment for HCV. The FDA identified 24 cases of HBV reactivation in 
HCV/HBV coinfected patients treated with DAAs including 2 deaths and 1patients who required 
transplantation. FDA issued a boxed warning on April 2016 
(www.fda.gov/Drugs/DrugSafety/ucm522932.htm)42. Therefore, concurrent antiviral treatment 
with an HBV nucleoside/nucleotide analogue is recommended in HBsAg-positive patients or 
if HBV DNA is detectable in HBsAg-negative, anti-HBc-positive patients, while patients with 
negative HBsAg and HBV DNA but positive anti-HBc ± anti-HBs should be monitored closely31. 
Alcohol consumption should be determined and quantified. Specific counseling to stop any 
harmful alcohol use should be given. In addition, components of the metabolic syndrome 
(weight, BMI, diabetes mellitus, hypertension, hyperlipidemia) should be determined and 
appropriate counseling and/or treatment initiated, as indicated. Other causes of chronic liver 
diseases such as hemochromatosis and others should also be excluded. 
As current treatment regimens are partially determined by the fibrosis stage and previous 
treatments, a detailed treatment history has to be obtained. The stage of fibrosis can be 
determined with either a liver biopsy or transient elastography (FibroScan®). In patients with 
cirrhosis, determination of liver function (Child-Pugh score) and assessment of portal 
hypertension are essential. DAA protease inhibitor-based treatment regimens should only be 
considered in patients with well compensated liver function (Child-Pugh A) and without prior 
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history of liver decompensation. 
Before deciding on the treatment regimen and treatment duration, it is crucial to know the 
HCV genotype and the current serum HCV RNA load. If the viral genotype has not been 
determined recently, HCV genotyping should be repeated. Testing for the presence of RAS 
prior to starting treatment should be performed as indicated in Tables 3A and 3B. 
In order to gather important real-life data on the natural history and treatment outcomes of 
HCV infection in Switzerland, we suggest to include HCV-infected patients in the Swiss Hepatitis 
C Cohort Study (SCCS), and (for HIV-coinfected patients) in the Swiss HIV Cohort Study 
(SHCS). 
 
Practical use of sofosbuvir 
SOF (Sovaldi®, Gilead Sciences, Foster City, CA) is a uridine nucleotide inhibitor of the HCV 
NS5B RNA-dependent RNA polymerase, with potent pangenotypic activity and a high barrier 
to resistance. It is administered at a dose of one 400-mg tablet per day, with or without food. It 
is reimbursed, with limitations (see above), since August 2014. 
SOF is generally well tolerated and has to be combined with another DAA and/or RBV (see 
Tables 3A and 3B for specific recommendations). The combination with PEG-IFN-α/RBV is 
no longer recommended due to the availability of very safe and efficient interferon-free 
combinations in all genotypes. The most commonly reported adverse effects are headache, 
fatigue and nausea. 
The risk of drug-drug interactions, notably with most antirejection and antiretroviral treatments, is 
low. However, coadministration of potent P-glycoprotein (P-gp) inducers, such as rifampicin, 
carbamazepine, phenytoin or St. John's wort should be avoided, as they significantly decrease 
the plasma concentration of SOF (www.hep-druginteractions.org). The combination of SOF and 
another DAA with amiodarone has been linked to instances of severe bradycardia and is 
therefore contraindicated. 
SOF and its main metabolite GS-331007 are eliminated predominantly by the kidney. 
Therefore, SOF should not be administered to patients with severe renal impairment 
(estimated glomerular filtration rate < 30 ml/min) or with end-stage renal disease until more 
data is available; expert advice is recommended. SOF exposure is not significantly changed 
in patients with mild liver function impairment, but it is increased about 2- to 2.5-fold in those 
with moderate to severe hepatic impairment. However, dose adaptations are not 
recommended in this situation. Therapeutic drug monitoring for SOF and GS-331007 is 
available at the Division of Clinical Pharmacology of the CHUV (www.chuv.ch/pcl). 
 
Practical use of the ledipasvir/sofosbuvir fixed-dose combination 
LDV is a NS5A inhibitor with potent activity against genotypes 1a, 1b, 4, 5 and 6 but lower 
activity against genotypes 2a and 3a. It is administered with or without food once daily at a 
dose of 90 mg in combination with SOF 400 mg as a fixed-dose combination single tablet 
(Harvoni®, Gilead Sciences, Foster City, CA). It is reimbursed, with the limitations above, since 
February 2015. 
LDV/SOF is generally well tolerated over 8-12-24 weeks of administration. The most 
commonly reported adverse effects are fatigue and headache. In patients who fail LDV/SOF 
NS5A resistance-associated substitutions (RASs) are detected in the majority of patients. The 
RASs can persist for many years, maybe forever. Expert advice is recommended before 
retreating these patients. 
The risk of drug-drug interactions, notably with most antirejection and antiretroviral treatments, is 
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low. However, coadministration of potent P-gp inducers, such as rifampicin, carbamazepine, 
phenytoin or St. John's wort should be avoided (see above). Proton pump inhibitors (PPI) at 
a dose equal to 20 mg omeprazole can be safely co-adminstered with LDV/SOF. Higher 
doses should be avoided, as this may decrease LDV levels, and PPI should not be taken before 
LDV/SOF. LDV/SOF should also not be combined with tipranavir boosted with ritonavir and 
rosuvastatin (www.hep-druginteractions.org). LDV/SOF increases exposure to tenofovir which 
warrants close monitoring for renal toxicity when LDV/SOF and tenofovir are co-administered. 
For the combination with amiodarone, see recommendations above. 
As discussed above, LDV/SOF should not be administered to patients with severe renal 
impairment (estimated glomerular filtration rate < 30 ml/min) or with end-stage renal disease 
until more data is available; expert advice is recommended. LDV/SOF in combination with 
ribavirin has been evaluated in patients with decompensated cirrhosis (Child-Pugh B and Child-
Pugh C 10-12 points) and no additional safety issues were reported. 
 
Practical use of the combination of ritonavir-boosted paritaprevir, ombitasvir 
and dasabuvir 
PTV/r, a ritonavir-boosted, first-generation, second-wave protease inhibitor, OBV, an NS5A 
inhibitor, and DSV, a non-nucleosidic polymerase inhibitor are reimbursed in Switzerland for 
the treatment of chronic hepatitis C of genotype 1 since February 2015, without limitations 
since August 1st 2017. PTV/r (75/50 mg) and OBV (12.5 mg) are coformulated in a single 
tablet (Viekirax®, AbbVie, North Chicago, IL) of which two have to be taken in the morning. 
DSV 250 mg (Exviera®, AbbVie) has to be taken twice daily. It is recommended to take 
these medications with food. There is a significant potential for drug-drug interactions. Hence, 
it is recommended to consult continuously updated databases such as the drug interactions 
database from the University of Liverpool (www.hep-druginteractions.org). 
Treatment with PTV/r, OBV and DSV is combined with RBV for patients with genotype 1a 
infection or cirrhosis. According to current recommendations RBV can be omitted for patients 
with genotype 1b infection with and without cirrhosis19, 28, 27. Standard treatment duration is 
12 weeks. The current Swiss label foresees extension to 24 weeks only for genotype 1a- 
infected cirrhotic patients with a previous null response. However according to EASL and 
AASLD guidelines treatment should be extended to 24 weeks in treatment naïve and PEG- 
IFN-α-RBV experienced genotype 1a patients with compensated cirrhosis. PTV/r and OBV 
have robust activity also against genotype 419, 20, 26. This combination has recently been 
approved in Switzerland also for patients with genotype 4 infection, without limitations since 
August 1st 2017. PTV/r, OBV and DSV can be used in patients with advanced renal 
impairment. However, expert advice is recommended in this situation. 
This combination is contraindicated in patients with decompensated cirrhosis (Child-Pugh B 
or C; http://www.fda.gov/Drugs/DrugSafety/ucm468634.htm). 
Combination therapy with PTV/r, OBV and DSV is generally well tolerated. Unconjugated 
hyperbilirubinemia due to inhibition of organic anion transporting polypeptide (OATP) 1B1 and 
OATP1B3 may be observed occasionally. The adverse effects of RBV are well known. 
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Practical use of simeprevir 
SMV (Olysio®, Janssen Therapeutics, Titusville, NJ) is a first generation, second wave 
protease inhibitor which is administered at a dose of 150 mg (one capsule) once daily. 
Importantly, in Switzerland SMV is no longer reimbursed, irrespective of the fibrosis stage. It is 
active in vitro against HCV genotypes 1, 2, 4, 5 and 6. SMV has to be used in combination 
with PEG-IFN-α and RBV or in combination with another DAA (e.g. SOF or DCV) with or 
without RBV as part of an IFN-free regimen. In Switzerland SMV is only approved in 
combination with PEG-IFN-α and RBV for patients with genotype 1a (without NS3 Q80K 
polymorphism), genotype 1b or genotype 4 infection. SMV in combination with SOF ± RBV 
for 12-24 weeks would be a well-tolerated, effective IFN-free regimen, which is licensed in 
the US and Europe for use in patients with genotype 1 and 4 infection, but is off-label in 
Switzerland. 
SMV is well tolerated and the most common side effects are rash, photosensitivity, pruritus 
and nausea. SMV is a known inhibitor of OATP1B1 and multidrug resistance-associated protein 
2 (MRP2) and, therefore, mild, transient hyperbilirubinemia can be observed in approximately 
10% of patients. 
There is a significant potential for drug-drug interactions. See package inserts and continuously 
updated online databases (e.g., www.hep-druginteractions.org) for known drug- drug 
interactions and contraindicated drugs. Commonly used drugs that are contraindicated in 
combination with SMV include, among others, carbamazepine, phenytoin, phenobarbital, 
clarithromycin, rifampicin, fluconazole, voriconazole, milk thistle, St. John's wort, some 
antiretroviral drugs including any protease inhibitor irrespective of boosting with ritonavir, 
efavirenz, delavirdine, etravirine, nevirapine and ritonavir. 
In patients with renal impairment no dosage adjustments are necessary. SMV should not be 
used in patients with decompensated cirrhosis (Child-Pugh B and C). 
 
Practical use of daclatasvir 
DCV (Daklinza®, Bristol-Myers Squibb, New York, NY) is an inhibitor of the HCV NS5A protein 
with pangenotypic activity. It is administered as an oral tablet of 60 mg once daily. DCV is 
approved in Switzerland since August 2015. It is metabolized by cytochrome P450 
isoenzymes, predominantly 3A4 (CYP3A4) and P-gp. Therefore, co-administration with strong 
inducers of CYP3A4 and/or P-gp (e.g. rifampicin, dexamethasone, St. John’s wort) is 
contraindicated. The dosage has to be reduced to 30 mg when combined with some inhibitors 
of CYP3A4 (e.g. atazanavir/ritonavir), and increased to 90 mg when combined with moderate 
inducers of CYP3A4 (e.g. efavirenz; see www.compendium.ch). However, DCV is dosed 60 
mg daily when combined with darunavir/ritonavir. Dose modification is not required in the 
elderly or in patients with renal or hepatic impairment. 
DCV is in general well tolerated. The most common adverse effects are headache, fatigue, 
nausea and diarrhea. DCV has been studied together with PEG-IFN-α + RBV, or as IFN-free 
combination therapy together with SOF or SMV. 
In Switzerland DCV is approved and reimbursed in combination with PEG-IFN-α and RBV for 
patients with genotype 4 infection and in combination with SOF for patients with genotype 3 
infection for a maximal treatment duration of 24 and 12 weeks, respectively. 
7 	  
Practical use of the grazoprevir/elbasvir fixed-dose combination 
 
GZR/EBR is a fixed-dose combination (Zepatier®, Merck, New Jersey, NJ) consisting of 100 
mg GZR and 50 mg EBR. GZR inhibits the NS3-4A protease and EBR the HCV NS5A protein. 
This combination shows activity against HCV genotypes 1 and 4. It is approved and 
reimbursed in Switzerland for genotype 1 and 4 infections, without limitation since July 1st 2017. 
GZR is a substrate of the OATP1B transporter and strongly interacts with OATP1B inhibitors 
(e.g. rifampicin) which are contraindicated. GZR and EBR are both substrates of CYP3A4 
and P-gp. Therefore, co-medications which significantly inhibit (e.g. ketoconazole) or induce 
(e.g. carbamazepine, phenytoin, flucloxacillin, St. John’s wort) CYP3A4 and P-gp are also 
contraindicated. The same applies for the class of HIV protease inhibitors, for efavirenz and 
etravirine. For co-medications with a moderate inhibition of CYP3A or P-gp liver enzymes 
need to be monitored. Dose modification in the elderly or in the patients with renal impairment 
is not necessary. GZR/EBR can be used in patients with advanced renal impairment. 
However, expert advice is recommended in this situation. In case of significant liver 
impairment (Child-Pugh B and C) GZR/EBR is contraindicated. 
The most common adverse effects are fatigue, headache, insomnia, nausea and diarrhea. 
Liver enzymes should be measured before treatment initiation and at week 8 during treatment 
because in 1% of the study patients an elevation has been observed. 
 
In patients with HCV genotype 1a baseline resistance testing has to be performed to identify 
potential NS5A polymorphisms (M28T/A, Q30E/H/R/G/K/L/D, L31M/V/F, H58D and Y93C/H/N) 
as these significantly reduce rates of SVR12 with a 12-week course of GZR/EBR. If such a 
polymorphism has been detected the total GZR/EBR treatment duration is 16 weeks in 
combination with weight-based RBV (1000 mg [< 75 kg] to 1200 mg [≥ 75 kg]). Resistance 
testing is reimbursed by the manufacturer of GZR/EBR. Prolongation of GZR/EBR treatment to 16 
weeks in combination with RBV is also indicated for patients with genotype 4 infection who 
failed a previous treatment with PEG-IFN-α and RBV (relapse excluded) (see Table 1). 
 
Table 1. Recommended regimens and durations of GZR/EBR ± RBV. 
 
Genotype Patient population Treatment Duration 
1a Treatment-naïve or PEG-IFN-α/RBV-experienced1 
without baseline NS5A polymorphisms2 
GZR/EBR 12 wks 
1a Treatment-naïve or PEG-IFN-α/RBV-experienced1 
with baseline NS5A polymorphisms2 
GZR/EBR 
+RBV 
16 wks 
1b Treatment-naïve or PEG-IFN-α/RBV-experienced1 GZR/EBR 12 wks 
4 Treatment-naïve or relapse after PEG-IFN-α/RBV GZR/EBR 12 wks 
4 PEG-IFN-α/RBV-experienced3 GZR/EBR 
+RBV 
16 wks 
 
1  Patients who have failed treatment with PEG-IFN-α/RBV in combination with a NS3-4A protease inhibitor 
(boceprevir, telaprevir, SMV, PTV/r) should be discussed with an expert. 
2 Resistance testing to identify/exclude NS5A polymorphisms (28, 30, 31, 58, 93) prior to the initiation of therapy is 
mandatory. 
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3 'Experienced' includes previous ‘virological breakthrough’, ‘partial response’ and ‘null response’. Non-cirrhotic 
patients who had a ‘relapse’ are treated like TN patients, i.e. with GZR/EBR for 12 wks. 
 
Practical use of the velpatasvir/sofosbuvir fixed-dose combination 
Velpatasvir (VEL) is an NS5A inhibitor with pangenotypic activity. It is administered once daily 
independently of food intake in a fixed-dose combination single pill containing 100 mg of VEL 
and 400 mg of SOF (Epclusa®, Gilead Sciences, Foster City, CA). It is reimbursed since 
January 2017 with the limitations outlined below. The most common side effects include sleep 
disturbances, headache and fatigue. 
VEL is metabolized by CYP2B6, CYP2C8 and CYP3A4 and is transported by P-gp, BCRP 
and OAT-transporters. Most drug-drug interactions are mild, but some drugs are 
contraindicated together with VEL (see www.hep-druginteractions.org); potent P-gp inducers 
such as rifampicin, some antiepileptic drugs or St John’s wort) or cytochrome-inducing drugs 
such as efavirenz significantly reduce VEL drug levels and should not be co-administered. 
With regard to co-administration of PPIs or amiodarone, the same restrictions apply as for 
LDV/SOF (see above). VEL/SOF is not recommended in patients with severe renal 
impairment (estimated glomerular filtration rate <30 ml/min) because of the substantially higher 
concentration of the SOF metabolites GS-331007 (see above). VEL/SOF has been studied in 
patients with decompensated cirrhosis27 and was generally well tolerated in this setting. Safety 
and efficacy of VEL/SOF were assessed in the phase III Astral studies27-29. This combination 
therapy achieved cure rates > 95% across all genotypes. Suboptimal SVR were only observed in 
genotype 3 infected cirrhotic or treatment- experienced patients with pre-existing NS5A RASs 
(particularly the Y93H substitution). Accordingly, AASLD and EASL recommendations foresee 
either to exclude this variant or to add RBV in this situation (see also Tables 3A and 3B). 
 
Table 2. Current reimbursement limitations of approved DAA according to Metavir stage 
(criteria for reimbursement independently of Metavir are listed above, p.2). 
 
DAA      Genotype       Metavir F0-F1 
 
Metavir F2-F4 
Liver stiffness ≥ 7.51 
SOF 1-6 not reimbursed reimbursed 
LDV/SOF 1 not reimbursed reimbursed2 
PTV/r/OBV + DSV 1 reimbursed reimbursed 
PTV/r/OBV 4 reimbursed reimbursed 
SMV3 1 and 4 not reimbursed not reimbursed 
DCV4 3 and 4 not reimbursed reimbursed 
GZR/EBR 1 and 4 reimbursed reimbursed 
VEL/SOF 1-6 not reimbursed reimbursed 
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1     As determined by FibroScan® on two occasions ≥ 3 months apart. 
2 Reimbursement is limited to 8 weeks in treatment-naive non-cirrhotic patients with F2 fibrosis and a serum 
HCV RNA < 6 x 106 IU/ml. 
3     SMV is only approved but no longer reimbursed (irrespective of fibrosis stage) in combination with PEG-IFN-α 
+ RBV (see text). 
4 DCV is approved and reimbursed in combination with PEG-IFN-α + RBV for patients with HCV genotype 4 
infection (24 weeks) and with SOF for patients with genotype 3 infection (12 weeks). 
 
 
HCV RNA monitoring on treatment 
 
It is recommended to determine HCV RNA at baseline, week 2 or 4 (assessment of 
adherence, optional), week 12 or 24 (end of treatment), and 12 or 24 weeks after the end of 
treatment (SVR12 or SVR24, respectively). 
 
Follow-up after SVR 
EASL recommends to retest HCV RNA 48 weeks after the end of treatment. Given the extremely 
high probability of permanent cure in patients with SVR, physicians may choose to omit this 
control. If HCV RNA is still negative, these patients can be considered as definitively cured. 
HCV RNA determination is no longer necessary, unless the patient has an ongoing or new risk 
behavior for HCV reinfection (illicit drug use, sexual practices that involve exchange of blood). 
Patients with an indication for HCC screening as recommended by international guidelines 
should remain under HCC surveillance every 6 months with ultrasound and alpha-fetoprotein 
(the role of alpha-fetoprotein is controversial). EASL recommends HCC screening for all patients 
with Metavir stage ≥ F3 or FibroScan > 9.5 kPa, other guidelines (e.g. EACS) recommend HCC 
screening for cirrhotic patients only. Patients with cirrhosis should undergo screening for 
esophageal varices as recommended in the Baveno VI consensus statement43. Patients 
without advanced liver disease (F0-F2; FibroScan ≤ 9.5 kPa) but with cofactors for liver 
disease progression (alcohol use, metabolic syndrome, non-alcoholic fatty liver disease etc.) 
should be periodically (once a year) assessed for liver disease progression. Patients 
without significant liver fibrosis (Metavir F0-F1; FibroScan < 7.5 kPa) and without risk factors 
for disease progression can be released from specialized care. 
 
Special patient populations 
 
Response rates to DAAs are similar in HCV-HIV-coinfected as compared to HCV- monoinfected 
patients. Therefore, treatment indications and regimens for HCV-HIV- coinfected patients should 
in general follow those of HCV-monoinfected patients. Specific recommendations for the 
management of HCV infection in HIV-infected patients are updated regularly by the European 
AIDS Clinical Society (www.eacsociety.org). Because of the frequent co-medication with 
antiretrovirals and further drugs, it is crucial to check for drug- drug interactions (www.hep-
druginteractions.org) before starting DAA treatments. However, in the large majority of patients, 
drug-drug interactions are manageable and should not be a barrier to starting DAA therapy. 
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Expert advice should be sought for patients with previous failure of a regimen comprising a 
DAA as well as patients with decompensated cirrhosis, renal insufficiency, pre- or post-liver 
transplantation, other organ transplants (e.g. bone marrow, lung, heart, kidney), HCC, acute 
hepatitis C and HCV genotype 5 or 6 infection. 
 
Recommended treatment options for patients with chronic hepatitis C 
Recommended treatment options are summarized in Table 3. The recommendations were 
adapted according to new data on the influence of RASs on SVR. For example, a pooled 
analysis of 35 studies demonstrated the impact of LDV-specific RASs on SVR30. Cure rates 
were suboptimal in patients with NS5A RASs before starting LDV/SOF, particularly in 
treatment-experienced patients. Accordingly, the updated tables provide separate 
recommendations for treatment-naïve and treatment-experienced patients. The updated 
SASL-SSI EOS is mostly in line with the EASL Recommendations of September 201631; 
differences are outlined in the footnotes to Tables 3A and 3B. In some instances, the 
recommended treatment regimens depend on the presence or absence of NS5A RASs. Of 
note, the reimbursement of resistance tests in Switzerland is uncertain with the exception of 
resistance tests before starting GZR/EBR (see above for further information). 
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Table 3. Recommended treatment options for patients with chronic hepatitis C. 
 
A. Treatment-naïve patients 
 
Genotype Non-cirrhotic Cirrhotic (Child-Pugh A) 
1a VEL/SOF for 12 wks 
LDV/SOF for 8-12 wks1 
GZR/EBR ± RBV for 12-16 wks2 
PTV/r/OBV+DSV+RBV 12 wks 
DCV + SOF for 12 wks 
VEL/SOF for 12 wks 
LDV/SOF ± RBV for 12(-24) wks3 
GZR/EBR ± RBV for 12-16 wks2 
PTV/r/OBV+DSV + RBV 12-24 wks4 
DCV + SOF ± RBV for 12(-24) wks3 
1b VEL/SOF for 12 wks 
LDV/SOF for 8-12 wks1 
GZR/EBR for 12 wks 
PTV/r/OBV + DSV 8-12 wks5 
DCV + SOF for 12 wks 
VEL/SOF for 12 wks 
LDV/SOF ± RBV for 12(-24) wks3 
GZR/EBR for 12 wks 
PTV/r/OBV + DSV 12 wks 
DCV+SOF ± RBV for 12(-24) wks3 
2 VEL/SOF for 12 wks6 VEL/SOF for 12 wks6 
3 VEL/SOF for 12 wks 
DCV + SOF for 12 wks 
VEL/SOF ± RBV for 12(-24) wks7 
DCV + SOF + RBV for 24 wks 
4 GZR/EBR for 12 wks 
VEL/SOF for 12 wks 
PTV/r/OBV + RBV for 12 wks 
GZR/EBR for 12 wks 
VEL/SOF for 12 wks 
PTV/r/OBV + RBV for 12 wks 
5 and 6 VEL/SOF for 12 wks VEL/SOF for 12 wks 
 
Color code: green = approved and reimbursed (please consult www.spezialitaetenliste.ch for eventual updates); 
blue = according to the current Swiss label, but with potential modifications of treatment duration and/or the 
addition of RBV; orange = approved in Switzerland but not reimbursed. 
 
1 Treatment may be shortened to 8 wks in treatment-naive (TN) patients with Metavir fibrosis stage ≤ F2 if their 
baseline HCV RNA is < 6 x 106 (6.8 log) IU/ml. Patients with fibrosis stage ≥F3 or with a baseline HCV RNA ≥ 6 
x106 (6.8 log) IU/ml should be treated for 12 weeks. 
2 12 wks without RBV in patients without baseline NS5A polymorphisms, 16 wks with RBV in those with NS5A 
polymorphisms (see Table 1). 
3 The current EASL Recommendations foresee LDV/SOF or SOF+DCV for 12 wks without RBV in treatment- 
naïve cirrhotics with genotype 1a or 1b infection. In cirrhotic patients with negative predictors of response such as 
platelet counts < 75 G/l and RASs that confer high-level resistance to NS5A inhibitors, addition of RBV can be 
considered. If these patients do not tolerate ribavirin, extension to 24 weeks can be considered. This is not 
foreseen in the current Swiss label. 
4 Extension to 24 wks is by the current Swiss label foreseen only for cirrhotic patients with subtype 1a and a 
previous null response. EASL recommends to treat all cirrhotic patients with subtype 1a for 24 weeks. 
5 EASL recommends 8 wks for treatment-naïve patients with ≤F2; this is not foreseen in the current Swiss label. 
6 SOF + RBV is no longer recommended due to suboptimal response rates. This is in line with the EASL and 
AASLD recommendation.  
7 Patients with cirrhosis should be treated with VEL/SOF + RBV for 12 weeks or with VEL/SOF for 24 wks if 
RBV-intolerant. Extension to 24 weeks in patients who cannot tolerate RBV requires approval by health 
insurances. If NS5A resistance testing is performed and demonstrates the absence of NS5A RAS Y93H, 
treatment can be performed with VEL/SOF for 12 weeks without RBV. 
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B. Treatment-experienced patients ([PEG-]IFN-α /RBV-experienced, DAA-naïve) 
 
Geno- 
type 
Non-cirrhotic Cirrhotic (Child-Pugh A) 
1a VEL/SOF for 12 wks 
LDV/SOF ± RBV for 12(-24) wks8 
GZR/EBR ± RBV for 12-16 wks9 
PTV/r/OBV + DSV + RBV 12 wks 
DCV + SOF ± RBV for 12(-24) wks8 
VEL/SOF for 12 wks 
LDV/SOF ± RBV for 12(-24) wks8 
GZR/EBR ± RBV for 12-16 wks9 
PTV/r/OBV+DSV+RBV 12-24 wks10 
DCV + SOF ± RBV for 12(-24) wks8 
VEL/SOF for 12 wks VEL/SOF for 12 wks 
LDV/SOF for 12 wks LDV/SOF ± RBV for 12(-24) wks11 
GZR/EBR for 12 wks GZR/EBR for 12 wks 
PTV/r/OBV + DSV 12 wks PTV/r/OBV + DSV 12 wks 
1b 
DCV + SOF for 12 wks DCV+SOF ± RBV for 12(-24) wks11 
2 VEL/SOF for 12 wks12 VEL/SOF for 12 wks12 
3 VEL/SOF ± RBV for 12(-24) wks13 
DCV + SOF ± RBV for 12(-24) wks8 
VEL/SOF ± RBV for 12(-24) wks13 
DCV + SOF + RBV for 24 wks 
4 GZR/EBR + RBV for 12-16 wks14 
VEL/SOF for 12 wks 
PTV/r/OBV + RBV for 12 wks 
GZR/EBR + RBV for 16 wks14 
VEL/SOF for 12 wks 
PTV/r/OBV + RBV for 12 wks 
5 and 6  VEL/SOF for 12 wks VEL/SOF for 12 wks 
 
8 EASL recommends adding RBV or extension to 24 wks (if RBV-intolerant) in patients with RASs that confer 
high-level resistance to NS5A inhibitors. Only the extension to 24 weeks (for LDV/SOF in cirrhotics; for DCV + 
SOF in non-cirrhotics) is foreseen in the current Swiss label. The addition of RBV is not foreseen in the current 
Swiss label. 
9 12 wks without RBV in patients without baseline NS5A polymorphisms, 16 wks with RBV in those with NS5A 
polymorphisms (see Table 1). 
10 Extension to 24 wks is by the current Swiss label foreseen only for cirrhotic patients with subtype 1a and a 
previous null response. EASL recommends to treat all cirrhotic patients with subtype 1a for 24 weeks. 
11 The current EASL recommendations foresee LDV/SOF or SOF+DCV for 12 wks without RBV in treatment- 
experienced cirrhotics with 1b infection. In cirrhotic patients with 1b infection with negative predictors of 
response such as platelet counts < 75 G/l and RASs that confer high-level resistance to NS5A inhibitors, 
addition of RBV can be considered. This is not foreseen in the current Swiss label. If these patients do not 
tolerate ribavirin, extension to 24 weeks can be considered. 
12 SOF + RBV is no longer recommended due to suboptimal response rates. This is in line with the EASL and 
AASLD recommendation.  
13 Treatment experienced patients without or with cirrhosis should be treated with VEL/SOF + RBV for 12 weeks or 
with VEL/SOF for 24 wks if RBV-intolerant. Extension to 24 weeks in patients who cannot tolerate RBV 
requires approval by health insurances. If NS5A resistance testing is performed and demonstrates the 
absence of NS5A RAS Y93H, treatment can be performed with VEL/SOF for 12 weeks without RBV. 
14 The current Swiss label foresees GZR/EBR for 12 wks without RBV in previous [PEG-]IFN-α/RBV relapsers 
(see Table 1). 
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